Spyre Therapeutics (SYRE) Other Gross PP&E Adjustments (2016 - 2024)
Historic Other Gross PP&E Adjustments for Spyre Therapeutics (SYRE) over the last 10 years, with Q4 2024 value amounting to -$7.1 million.
- Spyre Therapeutics' Other Gross PP&E Adjustments fell 6754.59% to -$7.1 million in Q4 2024 from the same period last year, while for Sep 2025 it was -$7.1 million, marking a year-over-year decrease of 103824.0%. This contributed to the annual value of -$7.1 million for FY2024, which is 6754.59% down from last year.
- Per Spyre Therapeutics' latest filing, its Other Gross PP&E Adjustments stood at -$7.1 million for Q4 2024, which was down 6754.59% from -$4.2 million recorded in Q4 2023.
- Spyre Therapeutics' 5-year Other Gross PP&E Adjustments high stood at $1.3 million for Q4 2020, and its period low was -$7.1 million during Q4 2024.
- For the 5-year period, Spyre Therapeutics' Other Gross PP&E Adjustments averaged around -$4.2 million, with its median value being -$5.3 million (2020).
- Its Other Gross PP&E Adjustments has fluctuated over the past 5 years, first soared by 15184.3% in 2020, then plummeted by 76240.25% in 2023.
- Spyre Therapeutics' Other Gross PP&E Adjustments (Quarter) stood at $1.3 million in 2020, then tumbled by 40.52% to $778000.0 in 2021, then dropped by 17.61% to $641000.0 in 2022, then plummeted by 762.4% to -$4.2 million in 2023, then tumbled by 67.55% to -$7.1 million in 2024.
- Its last three reported values are -$7.1 million in Q4 2024, -$4.2 million for Q4 2023, and -$6.0 million during Q2 2023.